2020 GU ASCO Presentations

The DCI Center for Prostate & Urologic Cancers has 31 abstracts accepted for presentation at the 2020 Genitourinary Cancers (GU) Symposium of the American Society of Clinical Oncology (ASCO) taking place Thursday, Feb. 13 through Saturday, Feb. 15 in San Francisco, California.

Held annually, researchers throughout the world gather for a three-day scientific retreat to share groundbreaking research in genitourinary malignancies. Over the course of the symposium, attendees will engage in educational sessions, keynote lectures, oral abstract presentations and poster sessions highlighting the latest, breakthrough science in prostate and urologic cancers.

“We are pleased to showcase our data at this year’s GU ASCO symposium and be a part of the cutting-edge research and paradigm shifts in clinical care for prostate and urologic cancers,” said Daniel George, MD, director of genitourinary oncology at Duke Cancer Institute. “This year, our team contributed to 31 publications selected for presentation overall, and 10 of which we will lead. We are committed to advancing our knowledge and moving science forward, and GU ASCO is a great platform to further research collaborations with peers in academics and private industry.”

DCI Center for Prostate & Urologic Cancers GU ASCO Abstracts:

Prostate Cancer

• Abstract 147: Circulating tumor cell (CTC) genomic signatures of hormone therapy resistance in men with metastatic castration-resistant prostate cancer (mCRPC)
  AUTHORS: Santosh Gupta, MD
   
• Abstract 184: AR-V7 and prediction of benefit with taxane therapy: Final analysis of PROPHECY
  AUTHOR: Andrew Armstrong, MD, ScM, FACP
   
• Abstract 183: Association of circulating tumor cell chromosomal instability with worse outcomes in men with mCRPC treated with abiraterone or enzalutamide.
  AUTHOR: Landon Brown, MD
   
• Abstract 96: Disulfiram (DSF) pharmacokinetics (PK) and copper PET imaging in a phase Ib study of intravenous (IV) copper loading with oral DSF for patients with metastatic castration-resistant prostate cancer (mCRPC).
  AUTHOR: Tian Zhang, MD, MHS
   
• Abstract 40: Overall survival (OS) in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving bicalutamide (BIC) followed by enzalutamide (ENZA) or abiraterone (ABI)
  AUTHOR: Daniel George, MD
• Abstract 102: KEYNOTE-365 cohort C updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
  AUTHOR: William Berry, MD

Kidney Cancer

• Abstract 731: Longitudinal multiplex cytokine analysis for patients (pts) with metastatic renal cell carcinoma (mRCC) treated with ipilimumab/nivolumab (I+N).
  AUTHOR: Tian Zhang, MD, MHS
   
• Abstract 637: A multicenter retrospective study to evaluate real-world clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) and brain metastasis treated with ipilimumab and nivolumab.
  AUTHOR: Landon Brown, MD
   
• Abstract 636: Provider referral patterns following nephrectomy in high-risk locoregional renal cell carcinoma.
  AUTHOR: Hannah Dzimitrowicz, MD
   
• Abstract TPS760: PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).
  AUTHOR: Tian Zhang, MD, MHS